---
schema_version: "secwatch.filing_event.v1"
accession: "0001516551-25-000028"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:07:35.434680+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience Q4 net loss $9.7M; Phase 2a obesity trial top-line data accelerated to late Q3 2025

## Summary
- Cash $68.4M at Dec 31, 2024; projected runway through at least Q1 2027.
- Phase 2a CBeyond trial enrolled 136 patients; interim analysis removed; data expected late Q3/early Q4 2025.
- Net loss FY2024 $26.6M vs $37.6M in 2023 (prior year included $21.2M IPR&D charge).
- R&D expense FY2024 $18.7M (up from $5.8M) driven by Phase 2 trial and manufacturing costs.
- Settled insurance litigation, received $2.0M cash proceeds in Q4 2024.

## SEC filing metadata
- accession: 0001516551-25-000028
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000151655125000028/0001516551-25-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000151655125000028/skye-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001516551-25-000028
- JSON: https://secwatch.observer/filing/0001516551-25-000028.json
- Plain text: https://secwatch.observer/filing/0001516551-25-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.